IMRX Earnings Prediction
The chart below shows how IMRX performed 10 days before and after its earnings report, based on data from the past quarters. Typically, IMRX sees a +11.02% change in stock price 10 days leading up to the earnings, and a -0.89% change 10 days following the report. On the earnings day itself, the stock moves by -2.74%. This data can give you a slight idea of what to expect for the next quarter's release.
IMRX Key Earning Data
2024/Q4
Year Over Year
Quarter Over Quarter
Total Revenue
455.00
-99.76%
-98.81%
Gross Margin
-1507.91%
17093.96%
-5037.49%
Operating Margin
-3073627.91%
52323.97%
8844.84%
Net Margin
-2911112.31%
51077.91%
8598.66%
EPS
-0.50
-21.95%
2.04%
No Data Available
IMRX Earnings Analysis
Immuneering Corporation Corporation (IMRX.O) Earnings Conference Call
Positive
Positive Point: Immuneering began the first Phase 1/2a trial of IMM-1-104 for RAS mutated solid tumors, marking a significant milestone in becoming a clinical stage oncology company.
- The company dosed the first patient in less than 2 months after receiving IND clearance, indicating efficient progress in clinical trial initiation.
Positive Point: Immuneering's unique deep cyclic inhibition approach aims to maximize therapeutic activity while providing improved tolerability and durability in cancer treatment.
- Preclinical data shows promising responses in approximately 85% of RAS-mutant models tested, showcasing potential for universal-RAS activity with IMM-1-104.
Positive Point: The company's oncology pipeline focus, with the suspension of the early stage neuroscience program, extends the projected cash runway into the fourth quarter of 2024.
- Focusing solely on oncology development allows Immuneering to prioritize resources and efforts towards advancing cancer therapies.
Positive Point: Immuneering presented abstracts on 2 programs at ASCO and the SITC Annual Meeting in 2022, demonstrating promise and potential in treating KRAS and NRAS mutant cancers.
- Immuneering's lead asset IMM-1-104 showed tumor growth inhibition in preclinical studies, outperforming other MEK inhibitors in certain RAS mutations.
Positive Point: The Phase 1/2a clinical trial for IMM-1-104 is progressing well, with robust enthusiasm from investigators and a focus on enrolling patients with any RAS mutation.
- Immuneering aims to report initial Phase 1 data in mid-2023, signaling a near-term milestone in evaluating the safety and efficacy of IMM-1-104 in humans.
Positive Point: Immuneering's financial updates indicate sufficient funding to support operations into the fourth quarter of 2024, providing stability for ongoing clinical trial initiatives and development efforts.
- Operating expenses in 2022 primarily reflect advancements in the IMM-1-104 program, demonstrating a strategic allocation of financial resources towards oncology pipeline development.
Negative
Negative:
- The company's operating expenses increased from $11.1 million in Q4 2021 to $14 million in Q4 2022, and from $34.8 million in FY 2021 to $51.9 million in FY 2022, primarily due to the advancement of IMM-1-104 into the Phase 1/2a clinical trial and increased employee-related costs.
- Net loss attributable to common stockholders increased from $10.8 million in Q4 2021 to $13.2 million in Q4 2022, and from $33.5 million in FY 2021 to $50.5 million in FY 2022, indicating a growing financial loss for the company.
- Cash, cash equivalents, and marketable securities decreased from $150.2 million as of December 31, 2021, to $105.5 million as of December 31, 2022, signaling a decline in the company's financial resources.
- The decision to suspend the early-stage neuroscience program and focus solely on oncology to extend the cash runway by one quarter into the fourth quarter of 2024, indicating a shift in priorities and potential limitations in diversification of research and development efforts.
